source
- Replimune to resubmit melanoma therapy RP1 to FDA after two prior rejectionsReplimune announced on Friday that it will again submit its advanced melanoma candidate, RP1, to the U.S. Food and Drug Administration for review. The company says the filing follows new discussion…
- GSK reports strong Phase 3 results for Ionis-licensed chronic hepatitis B therapyGSK disclosed data from two late‑stage trials of a chronic hepatitis B treatment it licensed from Ionis Pharmaceuticals. The studies evaluated the drug’s efficacy and safety in patients with chroni…